Myriad Genetics, Inc. MYD.F Stock
Myriad Genetics, Inc. Price Chart
Myriad Genetics, Inc. MYD.F Financial and Trading Overview
Myriad Genetics, Inc. stock price | 21.4 EUR |
Previous Close | 21 EUR |
Open | 20.8 EUR |
Bid | 20.8 EUR x 50000 |
Ask | 21 EUR x 50000 |
Day's Range | 20.8 - 20.8 EUR |
52 Week Range | 13.52 - 27.3 EUR |
Volume | 500 EUR |
Avg. Volume | 0 EUR |
Market Cap | 1.7B EUR |
Beta (5Y Monthly) | 1.82007 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.58 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 30.25 EUR |
MYD.F Valuation Measures
Enterprise Value | 1.84B EUR |
Trailing P/E | N/A |
Forward P/E | 80 |
PEG Ratio (5 yr expected) | -219.88 |
Price/Sales (ttm) | 2.4418426 |
Price/Book (mrq) | 2.0296643 |
Enterprise Value/Revenue | 2.655 |
Enterprise Value/EBITDA | -21.751 |
Trading Information
Myriad Genetics, Inc. Stock Price History
Beta (5Y Monthly) | 1.82007 |
52-Week Change | 38.15% |
S&P500 52-Week Change | 20.43% |
52 Week High | 27.3 EUR |
52 Week Low | 13.52 EUR |
50-Day Moving Average | 19.76 EUR |
200-Day Moving Average | 19.09 EUR |
MYD.F Share Statistics
Avg. Volume (3 month) | 0 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 81.56M |
Float | 68.59M |
Short Ratio | N/A |
% Held by Insiders | 2.09% |
% Held by Institutions | 102.49% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -21.044% |
Operating Margin (ttm) | -20.71% |
Gross Margin | 69.31% |
EBITDA Margin | -12.20% |
Management Effectiveness
Return on Assets (ttm) | -7.41% |
Return on Equity (ttm) | -16.37% |
Income Statement
Revenue (ttm) | 694.7M EUR |
Revenue Per Share (ttm) | 8.59 EUR |
Quarterly Revenue Growth (yoy) | 9.90% |
Gross Profit (ttm) | 476.4M EUR |
EBITDA | -84800000 EUR |
Net Income Avi to Common (ttm) | -146200000 EUR |
Diluted EPS (ttm) | -1.67 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 78.7M EUR |
Total Cash Per Share (mrq) | 0.97 EUR |
Total Debt (mrq) | 161.6M EUR |
Total Debt/Equity (mrq) | 19.35 EUR |
Current Ratio (mrq) | 1.826 |
Book Value Per Share (mrq) | 10.248 |
Cash Flow Statement
Operating Cash Flow (ttm) | -93000000 EUR |
Levered Free Cash Flow (ttm) | -107887504 EUR |
Profile of Myriad Genetics, Inc.
Country | Germany |
State | UT |
City | Salt Lake City |
Address | 320 Wakara Way |
ZIP | 84108 |
Phone | 801 584 3600 |
Website | https://myriad.com |
Industry | Diagnostics & Research |
Sector(s) | Healthcare |
Full Time Employees | 2600 |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. Further, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Q&A For Myriad Genetics, Inc. Stock
What is a current MYD.F stock price?
Myriad Genetics, Inc. MYD.F stock price today per share is 21.4 EUR.
How to purchase Myriad Genetics, Inc. stock?
You can buy MYD.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Myriad Genetics, Inc.?
The stock symbol or ticker of Myriad Genetics, Inc. is MYD.F.
Which industry does the Myriad Genetics, Inc. company belong to?
The Myriad Genetics, Inc. industry is Diagnostics & Research.
How many shares does Myriad Genetics, Inc. have in circulation?
The max supply of Myriad Genetics, Inc. shares is 91.66M.
What is Myriad Genetics, Inc. Price to Earnings Ratio (PE Ratio)?
Myriad Genetics, Inc. PE Ratio is now.
What was Myriad Genetics, Inc. earnings per share over the trailing 12 months (TTM)?
Myriad Genetics, Inc. EPS is -2.58 EUR over the trailing 12 months.
Which sector does the Myriad Genetics, Inc. company belong to?
The Myriad Genetics, Inc. sector is Healthcare.